Aurora Completes Significant Expansion of EU-GMP Manufacturing Facility in Germany

Aurora Completes Major Expansion of EU-GMP Manufacturing Facility in Germany

Aurora Cannabis Inc., a leading global medical cannabis company based in Canada, is thrilled to announce the completion of a monumental expansion at its facility located in Leuna, Germany. This strategic development is set to more than double the expected annual flower output, positioning Aurora to significantly augment its presence in the European market.

A New Dawn for Aurora Horizons

In recognition of this impressive transformation and to symbolize a fresh start, the facility has been renamed Aurora Horizon. The name reflects the optimism of the local team and their commitment to excellence in cannabis production. With this expansion, Aurora Horizon is not only boosting its production capabilities but is also enhancing its operational efficiency to cater to the burgeoning demand for medical cannabis in Europe, particularly in Germany.

The newly completed manufacturing site incorporates Aurora's renowned cultivation practices and proprietary genetics, integrating advanced technologies seen in its Canadian operations. Alex Miller, Aurora's EVP of Operations and Supply Chain, emphasized that this expansion strengthens their commitment to providing high-quality medical products while reinforcing their growth strategy in Europe.

Investment in Quality and Compliance

This expansion comes as a result of a multi-million-dollar investment aimed at bolstering local production capacity. Aurora has obtained an updated EU-GMP license for the newly built areas, affirming the facility's compliance with the stringent manufacturing standards governing the European market. The enhanced production capabilities not only promise to improve product quality and consistency but also position the facility to withstand the pressures of supply chain dynamics.

Aurora Horizon has seamlessly integrated innovative agricultural practices, utilizing state-of-the-art lighting and irrigation technologies, alongside rigorous post-harvest processes to ensure that each product meets the elevated expectations of quality that Aurora is known for. By adopting leading genetics from Aurora's Research and Development hub in British Columbia, Canada, the facility is equipped to achieve the high-performance benchmarks set by other locations in Aurora's global network.

Economic Impact and Job Creation

This expansion is expected to have a meaningful economic impact on the local region in Saxony-Anhalt, creating numerous jobs and contributing to local employment in cultivation and manufacturing. As one of only three domestic producers within Germany, Aurora is uniquely positioned to be a significant player in fostering job creation and economic growth, thus enriching the community.

Furthermore, Aurora's presence in the region aligns with their broader strategy of enhancing supply chain resilience, while fulfilling consumer demand for premier quality medical cannabis.

Looking Ahead

Aurora Cannabis is at the forefront of the global cannabis movement, with products available across Canada, Europe, Australia, and New Zealand. Their diversified brand portfolio features both adult-use and medical cannabis products, demonstrating a commitment to quality and innovation in all markets where they operate.

As Aurora embraces the future with the expanded operations at Aurora Horizon, it remains steadfast in its mission to improve lives by delivering high-quality cannabis products. The company continues to drive advancements in cultivation techniques and operational efficiencies, ensuring that patients across Europe have access to the best possible medical cannabis available.

In conclusion, the expansion of Aurora's EU-GMP manufacturing facility represents a significant achievement not only for the company but also for the industry as a whole. Aurora Cannabis Inc. is committed to opening the world to cannabis, and with facilities like Aurora Horizon, they are well on their way to achieving that vision.